Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC JBI-589 | 2308504-22-3 | C29H28FN5O | 5 MG
Supplier: Medchemexpress LLC HY1534505MG
JBI-589 is a non-covalent, orally bioavailable, isoform-selective inhibitor of PAD4 (Protein Arginine Deiminase 4). It has been shown to reduce CXCR2 expression and block neutrophil chemotaxis. This compound can decrease primary tumors and metastases, and also enhance the anti-tumor effect of checkpoint inhibitors. JBI-589 is suitable for use in cancer research.
- Reduces CXCR2 expression and blocks neutrophil chemotaxis
- Decreases primary tumors and metastases
- Enhances anti-tumor effect of checkpoint inhibitors
- Suitable for cancer research
- Inhibits citrullination of histone H3 in Phorbol 12-myristate 13-acetate-induced mouse neutrophils
- Significantly inhibits growth of primary tumors in mouse models
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?